ReviewThe journal of liquid biopsy2023
Implementation of the clinical practice of liquid biopsies for thoracic oncology the experience of the RespirERA university hospital institute (Nice, France).
Review in The journal of liquid biopsy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Detecting actionable mutations from matched plasma-based versus tissue next-generation sequencing in advanced non-small cell lung cancer: a retrospective single centre analysis on site.Journal of experimental & clinical cancer research : CR · 2025Article
- International society of liquid biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumors.The journal of liquid biopsy · 2025Review
- Liquid Biopsy: The Challenges of a Revolutionary Approach in Oncology.International journal of molecular sciences · 2025Review
- Clinical applications of circulating tumor cells in patients with solid tumors.Clinical & experimental metastasis · 2024Review
- The first issue of the official journal of the International Society of Liquid Biopsy:The journal of liquid biopsy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
According to international guidelines, it is mandatory to evaluate predictive biomarkers of targeted therapies and the response to immune check point inhibitors for patients with non-squamous non-small cell lung cancer (NS-NSCLC). For this purpose, a tissue sample is nowadays the gold standard, but biofluids, particularly peripheral blood, can be a complementary and sometimes an alternative approach to assess the status of different druggable genomic alterations of advanced NS-NSCLC. A liquid biopsy (LB) is an attractive approah for better treatment decision-making by thoracic oncologists for NSCLC patients in daily practice at both initial diagnosis and tumor progression. We describe the experience of a clinical and molecular pathology laboratory (LPCE, Nice, France) developing the use of in-house LB in thoracic oncology. Moreover, we report the changes in clinical care, the advantages, but also the possible constraints associated with implantation of LB in routine clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.